View in EDS

Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.

Saved in:
Bibliographic Details
Title: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
Authors: Gong J; Cedars-Sinai Medical Center, Los Angeles, CA., Mita AC; Cedars-Sinai Medical Center, Los Angeles, CA., Wei Z; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Cheng HH; University of Washington, Seattle, WA., Mitchell EP; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA., Wright JJ; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Ivy SP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Gray RC; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Bethesda, MD., Hamilton SR; City of Hope Comprehensive Cancer Center, Duarte, CA., Alva AS; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX., Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA.
Source: JCO precision oncology [JCO Precis Oncol] 2024 Apr; Vol. 8, pp. e2300406.
Publication Type: Clinical Trial, Phase II; Journal Article; Adaptive Clinical Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38603651
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gong+J%22">Gong J</searchLink>; Cedars-Sinai Medical Center, Los Angeles, CA.<br /><searchLink fieldCode="AU" term="%22Mita+AC%22">Mita AC</searchLink>; Cedars-Sinai Medical Center, Los Angeles, CA.<br /><searchLink fieldCode="AU" term="%22Wei+Z%22">Wei Z</searchLink>; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Cheng+HH%22">Cheng HH</searchLink>; University of Washington, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Mitchell+EP%22">Mitchell EP</searchLink>; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Wright+JJ%22">Wright JJ</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Ivy+SP%22">Ivy SP</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Wang+V%22">Wang V</searchLink>; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Gray+RC%22">Gray RC</searchLink>; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22McShane+LM%22">McShane LM</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Rubinstein+LV%22">Rubinstein LV</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Patton+DR%22">Patton DR</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Williams+PM%22">Williams PM</searchLink>; Frederick National Laboratory for Cancer Research, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Hamilton+SR%22">Hamilton SR</searchLink>; City of Hope Comprehensive Cancer Center, Duarte, CA.<br /><searchLink fieldCode="AU" term="%22Alva+AS%22">Alva AS</searchLink>; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.<br /><searchLink fieldCode="AU" term="%22Tricoli+JV%22">Tricoli JV</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Conley+BA%22">Conley BA</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Arteaga+CL%22">Arteaga CL</searchLink>; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX.<br /><searchLink fieldCode="AU" term="%22Harris+LN%22">Harris LN</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22O'Dwyer+PJ%22">O'Dwyer PJ</searchLink>; University of Pennsylvania, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Chen+AP%22">Chen AP</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Flaherty+KT%22">Flaherty KT</searchLink>; Massachusetts General Hospital Cancer Center, Boston, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101705370%22">JCO precision oncology</searchLink> [JCO Precis Oncol] 2024 Apr; Vol. 8, pp. e2300406.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Adaptive Clinical Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101705370 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-4284 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224734284%22">24734284 </searchLink><i>NLM ISO Abbreviation: </i>JCO Precis Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38603651
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/PO.23.00406
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e2300406
    Titles:
      – TitleFull: Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gong J
      – PersonEntity:
          Name:
            NameFull: Mita AC
      – PersonEntity:
          Name:
            NameFull: Wei Z
      – PersonEntity:
          Name:
            NameFull: Cheng HH
      – PersonEntity:
          Name:
            NameFull: Mitchell EP
      – PersonEntity:
          Name:
            NameFull: Wright JJ
      – PersonEntity:
          Name:
            NameFull: Ivy SP
      – PersonEntity:
          Name:
            NameFull: Wang V
      – PersonEntity:
          Name:
            NameFull: Gray RC
      – PersonEntity:
          Name:
            NameFull: McShane LM
      – PersonEntity:
          Name:
            NameFull: Rubinstein LV
      – PersonEntity:
          Name:
            NameFull: Patton DR
      – PersonEntity:
          Name:
            NameFull: Williams PM
      – PersonEntity:
          Name:
            NameFull: Hamilton SR
      – PersonEntity:
          Name:
            NameFull: Alva AS
      – PersonEntity:
          Name:
            NameFull: Tricoli JV
      – PersonEntity:
          Name:
            NameFull: Conley BA
      – PersonEntity:
          Name:
            NameFull: Arteaga CL
      – PersonEntity:
          Name:
            NameFull: Harris LN
      – PersonEntity:
          Name:
            NameFull: O'Dwyer PJ
      – PersonEntity:
          Name:
            NameFull: Chen AP
      – PersonEntity:
          Name:
            NameFull: Flaherty KT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2024 Apr
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2473-4284
          Numbering:
            – Type: volume
              Value: 8
          Titles:
            – TitleFull: JCO precision oncology
              Type: main
ResultId 1